Literature DB >> 10510346

A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes.

B Drénou1, V Blancheteau, D H Burgess, R Fauchet, D J Charron, N A Mooney.   

Abstract

MHC class II molecules have a crucial role in thymic selection and in generating Ag-specific T cell responses. There is extensive evidence for second messenger generation via MHC class II molecules, which can lead to apoptosis of B lymphocytes. We have examined HLA class II-mediated apoptosis in both normal and tumoral human B lymphocytes. Phosphatidylserine exposure and DNA fragmentation were observed in B cells within 24 h of stimulation via HLA class II. In marked comparison with Fas, the cell-permeable and irreversible caspase inhibitors zVAD-fmk and DEVD-fmk failed to inhibit HLA-DR-mediated apoptosis. No direct activation of caspase 3 was detected, and cleavage of pro-caspase 3 was not observed. Cleavage of poly(ADP-ribose) polymerase was detected via Fas but not via HLA class II. Although phosphatidylinositol-3-kinase has been implicated in HLA class I-mediated apoptosis, neither wortmannin nor LY294002 affected HLA class II-mediated apoptosis. CD95-sensitive cells were used to reveal that death occurred independently of CD95-CD95 ligand interactions. Overall, these data reveal a pathway of HLA-DR-mediated apoptosis that neither requires nor involves caspases. Moreover, it is phosphatidylinositol-3-kinase independent and Fas/CD95 independent. This pathway of HLA class II-mediated apoptosis could have an important role in the regulation of APC populations or in the control of malignant B lymphocyte proliferations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510346

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Identification of sample-specific sequences in mammalian cDNA and genomic DNA by the novel ligation-mediated subtraction (Limes).

Authors:  T E Hansen-Hagge; U Trefzer; A S zu Reventlow; K Kaltoft; W Sterry
Journal:  Nucleic Acids Res       Date:  2001-02-15       Impact factor: 16.971

Review 2.  A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules.

Authors:  Zoltan A Nagy; Nuala A Mooney
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

3.  Detection of channel proximity by nanoparticle-assisted delaying of toxin binding; a combined patch-clamp and flow cytometric energy transfer study.

Authors:  Bálint Rubovszky; Péter Hajdú; Zoltán Krasznai; Rezsõ Gáspár; Thomas A Waldmann; Sándor Damjanovich; László Bene
Journal:  Eur Biophys J       Date:  2005-03       Impact factor: 1.733

Review 4.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

5.  MHC class II structural requirements for the association with Igalpha/beta, and signaling of calcium mobilization and cell death.

Authors:  Lei Jin; John C Stolpa; Ryan M Young; Aimee E Pugh-Bernard; Yosef Refaeli; John C Cambier
Journal:  Immunol Lett       Date:  2007-12-26       Impact factor: 3.685

6.  MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals.

Authors:  Lei Jin; Paul M Waterman; Karen R Jonscher; Cindy M Short; Nichole A Reisdorph; John C Cambier
Journal:  Mol Cell Biol       Date:  2008-06-16       Impact factor: 4.272

7.  Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk.

Authors:  Xingguang Liu; Zhenzhen Zhan; Dong Li; Li Xu; Feng Ma; Peng Zhang; Hangping Yao; Xuetao Cao
Journal:  Nat Immunol       Date:  2011-03-27       Impact factor: 25.606

8.  Resistance to tumor necrosis factor-induced cell death mediated by PMCA4 deficiency.

Authors:  K Ono; X Wang; J Han
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

9.  Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.

Authors:  Rhona Stein; Zhengxing Qu; Susan Chen; David Solis; Hans J Hansen; David M Goldenberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

10.  Induction of complete remission of hypoplastic leukemia with antithymocyte globulin.

Authors:  Ayami Yoshimi; Chikako Nakamoto; Yoichi Nakamura; Koji Kato; Takaharu Matsuyama; Kazuko Kudo; Seiji Kojima
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.